{"id":"dexmedetomidine-0-5-microgram-kg","safety":{"commonSideEffects":[{"rate":"15-30","effect":"Hypotension"},{"rate":"10-25","effect":"Bradycardia"},{"rate":"5-15","effect":"Hypertension (transient, initial)"},{"rate":"5-10","effect":"Dry mouth"},{"rate":"5-10","effect":"Rebound hypertension on withdrawal"}]},"_chembl":null,"_fixedAt":"2026-03-30T14:05:32.244551","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dexmedetomidine binds with high selectivity to alpha-2 adrenergic receptors, particularly in the locus coeruleus and other brainstem regions, leading to decreased norepinephrine release and reduced neuronal firing. This results in a unique sedative state characterized by maintained airway reflexes and the ability to be aroused, along with analgesic and anxiolytic effects. The drug is commonly used for sedation in intensive care and procedural settings.","oneSentence":"Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that produces sedation, analgesia, and anxiolysis by activating presynaptic and postsynaptic alpha-2 receptors in the central nervous system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:32:37.960Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Sedation of intubated and mechanically ventilated patients in intensive care units"},{"name":"Sedation and analgesia for procedural sedation"},{"name":"Perioperative anxiolysis and analgesia"}]},"_fixedFields":["pubmed(3)"],"trialDetails":[],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"recentPublications":[{"date":"2015 Jun","pmid":"25753681","title":"Electrocardiographic and electrophysiologic effects of dexmedetomidine on children.","journal":"Pacing and clinical electrophysiology : PACE"},{"date":"1991 Jul","pmid":"1676567","title":"Dexmedetomidine prevents epinephrine-induced arrhythmias through stimulation of central alpha 2 adrenoceptors in halothane-anesthetized dogs.","journal":"Anesthesiology"},{"date":"1991 May","pmid":"1682907","title":"Assessment of the sedative effects of dexmedetomidine, an alpha 2-adrenoceptor agonist, with analysis of saccadic eye movements.","journal":"Pharmacology & toxicology"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Dexmedetomidine 0.5 microgram/kg","genericName":"Dexmedetomidine 0.5 microgram/kg","companyName":"Sindh Institute of Urology and Transplantation","companyId":"sindh-institute-of-urology-and-transplantation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist that produces sedation, analgesia, and anxiolysis by activating presynaptic and postsynaptic alpha-2 receptors in the central nervous system. Used for Sedation of intubated and mechanically ventilated patients in intensive care units, Sedation and analgesia for procedural sedation, Perioperative anxiolysis and analgesia.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}